Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Merck enhances ophthalmology portfolio with EyeBio acquisition
The deal, which was announced in May 2024, includes an upfront cash payment of $1.3bn and $1.7bn in milestone payments on meeting developmental, regulatory and commercial goals. Under
The deal, which was announced in May 2024, includes an upfront cash payment of $1.3bn and $1.7bn in milestone payments on meeting developmental, regulatory and commercial goals. Under
The approval of Leqembi (generic name: Lecanemab) in Israel marks a significant milestone, as Israel becomes the sixth territory to endorse the drug for Alzheimer’s treatment after the
Ambien CR (zolpidem tartrate extended-release tablets) is intended for the short-term management of insomnia, which is manifested by challenges in initiating sleep and/or maintaining sleep continuity. Ambien (zolpidem
This product different from other versions of fosaprepitant as it is free from Polysorbate 80 and requires no reconstitution or dilution, simplifying administration directly from the vial utilising
An armoured allogeneic “off-the-shelf”gamma delta CAR T cell therapy, ADI-270 targets CD70-positive cancers. ADI-270 is engineered to target CD70 by using CD27 as the natural receptor binding moiety.
This decision follows a positive recommendation from the Committee for Medicinal Products for Human Use and is based on the results of the FLAURA2 Phase III trial. The
This approval marks a significant milestone for the company, indicating that its product is therapeutically equivalent to the reference listed Tibsovo Tablets, 250mg of Servier Pharmaceuticals. Ivosidenib is
The funding will support ongoing clinical trials for X-Linked Retinitis Pigmentosa (XLRP) and advance the company’s Dry Age-related Macular Degeneration (dAMD) programme. The investment round included contributions from
A lead radiopharmaceutical of the company, 225Ac-FL-020 acts on prostate-specific membrane antigen (PSMA). The fast track programme of the FDA aims to expedite the development and regulatory review
This marks a significant advancement as sigx1094 is the world’s first targeted therapy for DGC, a condition with a notable lack of effective treatments. The company is set